William B. Schwartz Division of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.
William B. Schwartz Division of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.
Kidney Int. 2020 Dec;98(6):1402-1404. doi: 10.1016/j.kint.2020.10.005. Epub 2020 Oct 13.
Coronavirus disease 2019 (COVID-19) has affected the care and outcomes of patients treated with dialysis worldwide. In this issue of Kidney International, 3 reports highlight the disproportionately severe impact of COVID-19 on patients on dialysis, noting its high prevalence, particularly among patients receiving in-center dialysis. This likely reflects patients' limited ability to physically distance as well as community exposures, including residence in areas with high rates of infection. Patients on dialysis are at extremely high risk should they develop COVID-19, with short-term mortality of 20% or higher. Accordingly, it is imperative that the kidney community intervenes to reduce the threat of COVID-19 in this vulnerable population by focusing on modifiable factors, including universal masking of patients and staff and enhanced screening, including testing for COVID-19 in the patients who are asymptomatic during times of high local prevalence.
2019 年冠状病毒病（COVID-19）已影响到全球接受透析治疗患者的护理和结局。本期《国际肾脏》中有 3 篇报道重点介绍了 COVID-19 对透析患者的严重影响不成比例，特别是在接受中心透析的患者中更为常见。这可能反映出患者在身体上保持距离的能力有限，以及社区暴露，包括居住在感染率高的地区。透析患者如果感染 COVID-19，其短期死亡率会高达 20%或更高。因此，肾脏科社区必须通过关注可改变的因素，包括对患者和工作人员进行普遍戴口罩以及加强筛查，包括在当地流行期间对无症状患者进行 COVID-19 检测，来介入以降低这一脆弱人群感染 COVID-19 的威胁。
